To minimize confounding factors that may affect our evaluation of albumin's effect on mortality, we excluded patients with a known history of End-Stage Liver Disease (ESLD), liver cirrhosis, or nephrotic syndrome on presentation since these medical conditions may independently alter the albumin levels [10]. This evidence concerns the gene ALB and End Stage Liver Disease.